SCHEMBL719244

SCHEMBL719244

COc1c(C(O)C2CCCCC2)oc2ccc(F)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.44
RAB9A P51151 2/20 0.44
HTR2C P28335 2/20 0.35
CNR1 P21554 3/20 0.35
CNR2 P34972 3/20 0.35
DRD2 P14416 1/20 0.33
ADRA2B P18089 1/20 0.33
DRD1 P21728 1/20 0.33
HTR2A P28223 1/20 0.33
HRH1 P35367 1/20 0.33
ADRA1B P35368 1/20 0.33
OPRK1 P41145 1/20 0.33
HTR2B P41595 1/20 0.33
KCNQ1 P51787 1/20 0.33
KCNH2 Q12809 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33
MAPT P10636 3/20 0.33
TP53 P04637 1/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718925 0.84 NPC1 (0.55) NPC1RAB9AOPRK1MAPTKDM4E
SCHEMBL718548 0.82 RAB9A (0.53) NPC1RAB9AOPRK1MAPTKDM4E
SCHEMBL721039 0.76 NPC1 (0.44) NPC1RAB9AHTR2CHTR2AKDM4E
SCHEMBL718063 0.74 RAB9A (0.57) NPC1RAB9AMAPTTP53KDM4E
SCHEMBL718236 0.73 NPC1 (0.52) NPC1RAB9ACNR1CNR2MAPT
SCHEMBL719030 0.73 RAB9A (0.47) NPC1RAB9AMAPTTP53KDM4E
SCHEMBL717053 0.71 NPC1 (0.45) NPC1RAB9AKCNH2ALDH1A1KMT2A
SCHEMBL718379 0.71 NPC1 (0.52) NPC1RAB9AHTR2CHTR2AOPRK1
SCHEMBL25697970 0.70 KCNH2 (0.42) HTR2CDRD2ADRA2BDRD1HTR2A
SCHEMBL721192 0.68 MCL1 (0.45) NPC1RAB9AOPRK1KCNH2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885HTR2C 2255/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885HTR2C 2255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.